

ONLINE APPENDIX 1: Author Relationships With Industry and Other Entities (Comprehensive)— 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Gordon F. Tomaselli, Chair	Johns Hopkins School of Medicine—Chief of Cardiology	<ul style="list-style-type: none"> • PhaseBio 	None	None	None	<ul style="list-style-type: none"> • American Heart Association* • Johns Hopkins School of Medicine† 	None
Kenneth W. Mahaffey, Vice Chair	Stanford Center for Clinical Research—Director; Stanford Department of Medicine—Vice-Chair of Clinical Research, Department of Medicine Stanford Center for Clinical Research	<ul style="list-style-type: none"> • Ablynx • AstraZeneca† • Boehringer Ingelheim Pharmaceuticals† • Bristol Myers Squibb† • Elsevier • GSK • Janssen Pharmaceuticals • Merck • Myokardia • Novartis • Oculeve • Portola • Radiometer • Springer • Theravance, Inc. • WebMD 	None	None	None	<ul style="list-style-type: none"> • Afferent† • Amgen • AstraZeneca • Ferring Pharmaceuticals • Medtronic • Merck • Sanofi • St Jude • Verily (Google) 	None
Adam Cuker	University of Pennsylvania—Assistant Professor and Pathology & Laboratory Medicine	<ul style="list-style-type: none"> • Amgen • Biogen-Idec • Genzyme† 	None	None	<ul style="list-style-type: none"> • Spark Therapeutics† • T2Biosystems* 	None	None
Paul P. Dobesh	University of Nebraska Medical	<ul style="list-style-type: none"> • AstraZeneca • Boehringer Ingelheim 	None	None	None	None	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Center—AQ Cardiology Professor of Pharmacy Practice, College of Pharmacy	<ul style="list-style-type: none"> • Daiichi Sankyo • Janssen Pharmaceuticals • Pfizer 					
John U. Doherty	Jefferson Medical College of Thomas Jefferson University—Professor of Medicine	None	None	None	None	None	None
John W. Eikelboom	McMaster University—Associate Director, Department of Medicine	<ul style="list-style-type: none"> • AstraZeneca† • Bayer† • Boehringer Ingelheim† • Bristol Myers Squibb† • Daiichi-Sankyo • Eli Lilly • GlaxoSmithKline • Haemoscope • Pfizer† • Sanofi-aventis 	None	None	<ul style="list-style-type: none"> • Bayer† • Boehringer Ingelheim† • Bristol Myers Squibb† • GlaxoSmithKline† • Pfizer† • Sanofi-aventis† 	None	None
Roberta Florido	Johns Hopkins School of Medicine—Fellow in Cardiovascular Medicine	None	None	None	None	None	None
William Hucker	Massachusetts General Hospital—Fellow in Cardiovascular Medicine	None	None	None	None	None	None
Roxana Mehran	Mount Sinai Medical Center—Professor of Medicine	<ul style="list-style-type: none"> • Boston Scientific • Cardiovascular Systems Inc • Janssen Pharmaceuticals • Johnson & Johnson • Medscape • Merck • Osprey • Shanghai BraccoSine Pharmaceutical Corp 	None	None	<ul style="list-style-type: none"> • Abbott Vascular† • AstraZeneca† • AUM Cardiovascular Inc. † • Bayer† • Beth Israel Deaconess Medical Center† • Bristol Myers Squibb† • CSL Behring† • Eli Lilly/DSI† • Medtronic† • Novartis† 	<ul style="list-style-type: none"> • OrbusNeich* • WebMD • National Heart, Lung & Blood Institute • SCAI* • Wiley Blackwell Publishing Company 	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
	Department of Pharmacy Services						

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

* No financial benefit

† Significant relationship

ACC indicates American College of Cardiology; SCAI, Society for Cardiac Angiography and Interventions.